Search

Your search keyword '"Orlic, D."' showing total 136 results
Start Over Author "Orlic, D." Search Limiters Full Text
136 results on '"Orlic, D."'

1. Diagnostic accuracy of instantaneous wave-free ratio at rest and during dobutamine provocation to assess myocardial bridging relevance

Author

Aleksandric, S, primary, Al-Lamee, R, additional, Djordjevic-Dikic, A, additional, Giga, V, additional, Tesic, M, additional, Banovic, M, additional, Zobenica, V, additional, Vukcevic, V, additional, Tomasevic, M, additional, Stojkovic, S, additional, Orlic, D, additional, Nedeljkovic, M, additional, Stankovic, G, additional, Davies, J, additional, and Beleslin, B, additional

Published
2022
Full Text
View/download PDF

2. Cut-off value of coronary flow velocity reserve obtained by transthoracic Doppler echocardiography during intravenous infusion of dobutamine for diagnosis of functional significant myocardial bridging

Author

Aleksandric, S, primary, Djordjevic-Dikic, A, additional, Tesic, M, additional, Giga, V, additional, Dobric, M, additional, Banovic, M, additional, Boskovic, N, additional, Juricic, S, additional, Vukcevic, V, additional, Tomasevic, M, additional, Stojkovic, S, additional, Orlic, D, additional, Nedeljkovic, M, additional, Stankovic, G, additional, and Beleslin, B, additional

Published
2021
Full Text
View/download PDF

6. A two year echocardiographic follow-up of patients with chronic total occlusion treated with percutaneous coronary intervention or receiving only medical therapy

Author

Juricic, S, primary, Petrovic, O, additional, Tesic, M, additional, Dobric, M, additional, Dikic, M, additional, Mehmedbegovic, Z, additional, Zivkovic, M, additional, Vukcevic, V, additional, Aleksandric, S, additional, Milasinovic, D, additional, Tomasevic, M, additional, Orlic, D, additional, Stankovic, G, additional, Beleslin, B, additional, and Stojkovic, S, additional

Published
2020
Full Text
View/download PDF

7. P284 Patients with reduced systolic function benefit most from recanalisation of chronic total occlusion

Author

Juricic, S, primary, Petrovic, O, additional, Tesic, M, additional, Dobric, M, additional, Orlic, D, additional, Aleksandric, S, additional, Trifunovic-Zamaklar, D, additional, Vukcevic, V, additional, Djordjevic-Dikic, A, additional, Mehmedbegovic, Z, additional, Milasinovic, D, additional, Zivkovic, M, additional, Stankovic, G, additional, Beleslin, B, additional, and Stojkovic, S, additional

Published
2020
Full Text
View/download PDF

12. Cardiopoietic cell therapy for advanced ischemic heart failure : results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

Author

Bartunek, Jozef, Terzic, Andre, Davison, Beth A, Filippatos, Gerasimos S, Radovanovic, Slavica, Beleslin, Branko, Merkely, Bela, Musialek, Piotr, Wojakowski, Wojciech, Andreka, Peter, Horvath, Ivan G, Katz, Amos, Dolatabadi, Dariouch, El Nakadi, Badih, Arandjelovic, Aleksandra, Edes, Istvan, Seferovic, Petar M, Obradovic, Slobodan, Vanderheyden, Marc, Jagic, Nikola, Petrov, Ivo, Atar, Shaul, Halabi, Majdi, Gelev, Valeri L, Shochat, Michael K, Kasprzak, Jaroslaw D, Sanz Ruiz, Ricardo, Heyndrickx, Guy R, Nyolczas, Noémi, Legrand, Victor, Guédès, Antoine, Heyse, Alex, Moccetti, Tiziano, Fernandez Aviles, Francisco, Jimenez Quevedo, Pilar, Bayes Genis, Antoni, Hernandez Garcia, Jose Maria, Ribichini, Flavio, Gruchala, Marcin, Waldman, Scott A, Teerlink, John R, Gersh, Bernard J, Povsic, Thomas J, Henry, Timothy D, Metra, Marco, Hajjar, Roger J, Tendera, Michal, Behfar, Atta, Alexandre, Bertrand, Seron, Aymeric, Stough, Wendy Gattis, Sherman, Warren, Cotter, Gad, Wijns, W. i. l. l. i. a. m. Collaborators Clinical investigators, Dens, sites Belgium: Ziekenhuis Oost Limburg: J., Dupont, M., Mullens, W., Janssens, M., Dolatabadi, Hoˆpital Civil de Charleroi: D., De Bruyne, Y., Lalmand, J., Dubois, P., El Nakadi, B., Aminian, A., De Vuyst, E., Gurnet, P., Gujic, M., Blankoff, I., Guedes, CHU Mont Godinne UCL: A., Gabriel, L., Seldrum, S., Doyen, C., Andre´, M., Heyse, AZ Glorieux: A., Van Durme, F., Verschuere, J., Legrand, Domaine Universitaire du Sart Tilman: V., Gach, O., D’Orio, V., Davin, L., Lancellotti, P., Baudoux, E., Ancion, A., Dulgheru, R., Vanderheyden, OLV Ziekenhuis Aalst – Cardiologie: M., Bartunek, J., Wijns, W., Verstreken, S., Penicka, . M., Gelev, P. Meeus Bulgaria: Tokuda Hospital Sofia: V., Zheleva Kichukova, I., Parapunova, R., Melamed, R., Sardovski, S., Radev, O., Yordanov, A., Radinov, A., Nenov, D., Amine, I., Petrov, City Hospital Clinic Cardiology Center: I., Kichukov, K., Nikitasov, L., Stankov, Z., Stoyanov, H., Tasheva Dimitrova, I., Angelova, M., Dimitrov, E., Minchev, M., Garvanski, I., Botev, C., Polomski, P., Alexandrovska University Hospital, Vassilev, Sofia: D., Karamfiloff, K., Tarnovska Kadreva, R., Vladimirova, L., Dimitrov, G., Hadzhiev, E., Tzvetkova, G., Andreka, . M. Atanasova Hungary: Gottsegen Gyo¨ rgy Orszagos Kardiologiai Inte´zet: P., Fontos, G., Fabian, J., Csepregi, A., Uzonyi, G., Gelei, A., Edes, Debreceni Egyetem Orvos e´s Ege´szse´gtudomanyi Centrum Altalanos Orvostudomanyi Kar Kardiologia Inte´zet: I., Balogh, L., Vajda, G., Darago, A., Gergely, S., Fulop, T., Jenei, C., Horvath, Pe´csi Tudomanyegyetem Klinikai Ko¨zpont Szıvgyogyaszati Klinika: I., Magyari, B., Nagy, A., Cziraki, A., Faludi, R., Kittka, B., Alizadeh, H., Merkely, Semmelweis Egyetem Varosmajori Szıv e´s Ergyogyaszati Klinika: B., Geller, L., Farkas, P., Szombath, G., Foldes, G., Skopal, J., Kovacs, A., Kosztin, A., Gara, E., Sydo, N., Nyolczas, MH Ege´szse´gu¨gyi Ko¨zpont Kardiologiai Osztaly: N., Kerecsen, G., Korda, A., Kiss, . M., Borsanyi, T., Polgar, B., Muk, B., Sharif, Z. Bari Ireland: HRB Clinical Research Facility: F., Atar, Y. M. Smyth Israel:Western Galilee Hospital: S., Shturman, A., Akria, L., Kilimnik, M., Brezins, M., Halabi, Ziv Medical Center: M., Dally, N., Goldberg, A., Aehab, K., Rosenfeld, I., Levinas, T., Saleem, D., Katz, Barzilai Medical Center: A., Plaev, T., Drogenikov, T., Nemetz, A., Barshay, Y., Jafari, J., Orlov, I., Nazareth Hospital EMMS: M. Omory, N. Kogan Nielsen, Shochat, Hillel Yaffe Medical Center: M., Shotan, A., Frimerman, A., Meisel, S., Asif, A., Sofer, O., Blondheim, D. S., Vazan, A., Metra, L. Arobov Italy: A. O. Spedali Civili di Brescia: M., Bonadei, I., Inama, L., Chiari, E., Lombardi, C., Magatelli, M., Russo, D., Lazzarini, V., Carubelli, V., Vassanelli, AOUI Verona – Borgo Trento Hospital: C., Ribichini, Flavio Luciano, Bergamini, C., Krampera, Mauro, Cicoria, M. A., Zanolla, L., Dalla Mura, D., Gambaro, A., Rossi, A., Pesarini Poland: Jagiellonian University Department of Cardiac, G., Musialek, Vascular Diseases at John Paul II Hospital in Krakow: P., Mazurek, A., Drabik, L., Ka˛dzielski, A., Walter, Z., Dzieciuch Rojek, M., Rubis, P., Plazak, . W., Tekieli, L., Podolec, J., Orczyk, W., Sutor, U., Zmudka, K., Olszowska, M., Podolec, P., Gruchala, Uniwersyteckie Centrum Kliniczne: M., Ciecwierz, D., Mielczarek, M., Burakowski, S., Chmielecki, M., Zielinska, M., Frankiewicz, A., Wdowczyk, J., Stopczynska, I., Bellwon, J., Mosakowska, K., Nadolna, R., Wroblewska, J., Rozmyslowska, M., Rynkiewicz, M., Marciniak, I., Raczak, G., Tarnawska, M., Taszner, M., Kasprzak, Bieganski Hospital: J., Plewka, M., Fiutowska, D., Rechcinski, T., Lipiec, P., Sobczak, M., Weijner Mik, P., Wraga, M., Krecki, R., Markiewicz, M., Haval Qawoq, D., Wojakowski, Gornosla˛skie Centrum Medyczne Sla˛skie j. Akademii Medycznej: W., Ciosek, J., Dworowy, S., Gaszewska Zurek, E., Ochala, A., Cybulski, W., Jadczyk, T., Wanha, W., Parma, Z., Kozlowski, M., Dzierzak, M., Markiewicz Serbia: Clinical Hospital Center Zvezdara, M., Arandjelovic, Cardiology Clinic: A., Sekularac, N., Boljevic, D., Bogdanovic, A., Zivkovic, S., Cvetinovic, N., Loncar, G., Clinical Centre of Serbia, Beleslin, Cardiology Clinic: B., Nedeljkovic, M., Trifunovic, D., Giga, V., Banovic, M., Nedeljkovic, I., Stepanovic, J., Vukcevic, V., Djordjevic Dikic, A., Dobric, M., Obrenovic Kircanski, B., Seferovic, Cardiology Clinic: P., Orlic, D., Tesic, M., Petrovic, O., Milinkovic, I., Simeunovic, D., Jagic, Clinical Center of Kragujevac: N., Tasic, M., Nikolic, D., Miloradovic, V., Djurdjevic, P., Sreckovic, M., Zornic, N., Clinical Hospital Center Bezanijska Kosa, Radovanovic, Cardiology Department: S., Saric, J., Hinic, S., Djokovic, A., Ðordevic, S., Bisenic, V., Markovic, O., Stamenkovic, S., Malenkovic, V., Tresnjak, J., Misic, G., Cotra, D., Tomovic, L., Vuckovic, V., Clinic of Emergency Internal Medicine, Obradovic, Military Medical Academy: S., Jovic, Z., Vukotic, S., Markovic, D., Djenic, N., Ristic Andjelkov, A., Bayes Genis, D. Ljubinka Spain: Hospital Universitario Germans Trias I. Pujol: A., Rodriguez Leor, O., Labata, C., Vallejo, N., Ferrer, E., Batlle, M., Fernandez Aviles, Hospital General Universitario Gregorio Mara~non: F., Sanz Ruiz, R., Casado, A., Loughlin, G., Zatarain, E., Anguita, J., Ferna ndez Santos, M. E., Pascual, C., Bermejo, J., Hernandez Garcia, Hospital Clinico Universitario Virgen de la Victoria: J. M., Jimenez Navarro, M., Dominguez, A., Carrasco, F., Mu~noz, A., Garcia Pinilla, J. M., Ruiz, J., Queipo de Llano, M. P., Hernandez, A., Fernandez, A., Jimenez Quevedo, Hospital Clinico San Carlos: P., Guerra, R., Biagioni, C., Gonzalez, R. A., Gomez deDiego, J. J., Mansson Broberg, L. Perez de Isla Sweden: Karolinska University Hospital: A., Sylve´n, C., Leblanc, K., Winter, R., Blomberg, P., Gunyeli, E., Ruck, A., Silva, C., Fo¨rstedt Switzerland: CardioCentro Ticino, J., Moccetti, Switzerland: T., Rossi, M., Pasotti, E., Petrova, I., Crljenica, C., Monti, C., Murzilli, R., Su¨rder, D., Moccetti, M., Turchetto, L., Locicero, V., Chiumiento, L., Maspoli, S., Mombelli, M., Anesini, A., Biggiogero, M., Ponti, G., Camporini, C., Polledri, S., Hill, G. Dolci United Kingdom: Kings College Hospital: J., Plymen, C., Amin Youssef, G., Mcdonagh, T., Drasar, E., Mijovic, A., Jouhra, F., Mcloman, D., Dworakowski, R., Webb, I., Byrne, J., and Potter, V.

Subjects
0301 basic medicine, Male, Cardiopoiesis, Cardiovascular disease, Disease severity, Marker, Precision medicine, Regenerative medicine, Stem cell, Target population, Adult, Aged, Double-Blind Method, Female, Heart Failure, Humans, Mesenchymal Stem Cell Transplantation, Middle Aged, Myocardial Ischemia, Prospective Studies, Treatment Outcome, Young Adult, Cardiology and Cardiovascular Medicine, Cell- and Tissue-Based Therapy, mesenchymal stem-cells, 030204 cardiovascular system & hematology, Cardiorespiratory Medicine and Haematology, outcomes, Fast-Track Clinical Research, Sudden cardiac death, 0302 clinical medicine, Ischemia, cardiovascular disease, Clinical endpoint, target population, CHART Program, Ejection fraction, bone-marrow, Heart Failure/Cardiomyopathy, 3. Good health, Cohort, Cardiology, Fast Track, disease severity, delivery, medicine.medical_specialty, precision medicine, Clinical Sciences, regenerative medicine, 03 medical and health sciences, cardiopoiesis, Internal medicine, medicine, Adverse effect, marker, disease, business.industry, medicine.disease, mortality, Confidence interval, Clinical trial, stem cell, Editor's Choice, 030104 developmental biology, predictors, Cardiovascular System & Hematology, Heart failure, business
Abstract

Altres ajuts: This work was supported by Celyad, SA (Mont-Saint-Guibert, Belgium). Celyad has received research grants from the Walloon Region (Belgium, DG06 funding). Cardiopoietic cells, produced through cardiogenic conditioning of patients' mesenchymal stem cells, have shown preliminary efficacy. The Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial aimed to validate cardiopoiesis-based biotherapy in a larger heart failure cohort. This multinational, randomized, double-blind, sham-controlled study was conducted in 39 hospitals. Patients with symptomatic ischaemic heart failure on guideline-directed therapy (n = 484) were screened; n = 348 underwent bone marrow harvest and mesenchymal stem cell expansion. Those achieving > 24 million mesenchymal stem cells (n = 315) were randomized to cardiopoietic cells delivered endomyocardially with a retention-enhanced catheter (n = 157) or sham procedure (n = 158). Procedures were performed as randomized in 271 patients (n = 120 cardiopoietic cells, n = 151 sham). The primary efficacy endpoint was a Finkelstein–Schoenfeld hierarchical composite (all-cause mortality, worsening heart failure, Minnesota Living with Heart Failure Questionnaire score, 6-min walk distance, left ventricular end-systolic volume, and ejection fraction) at 39 weeks. The primary outcome was neutral (Mann–Whitney estimator 0.54, 95% confidence interval [CI] 0.47–0.61 [value > 0.5 favours cell treatment], P = 0.27). Exploratory analyses suggested a benefit of cell treatment on the primary composite in patients with baseline left ventricular end-diastolic volume 200–370 mL (60% of patients) (Mann–Whitney estimator 0.61, 95% CI 0.52–0.70, P = 0.015). No difference was observed in serious adverse events. One (0.9%) cardiopoietic cell patient and 9 (5.4%) sham patients experienced aborted or sudden cardiac death. The primary endpoint was neutral, with safety demonstrated across the cohort. Further evaluation of cardiopoietic cell therapy in patients with elevated end-diastolic volume is warranted.

Published
2017

13. P5510Stress-induced myocardial ischemia in patients with myocardial bridging: correlations with fractional flow reserve and quantitative coronary angiography measurements during dobutamine infusion

Author

Aleksandric, S, primary, Djordjevic-Dikic, A, additional, Stepanovic, J, additional, Dobric, M, additional, Giga, V, additional, Stankovic, G, additional, Vukcevic, V, additional, Tomasevic, M, additional, Stojkovic, S, additional, Orlic, D, additional, Saponjski, M, additional, Nedeljovic, M, additional, Juricic, S, additional, Petrovic, M T, additional, and Beleslin, B, additional

Published
2018
Full Text
View/download PDF

14. P3579Prospective randomised comparison of percutaneous coronary intervention and optimal medical therapy in patients with chronic total occlusion

Author

Juricic, S, primary, Petrovic, O, additional, Tesic, M, additional, Dobric, M, additional, Aleksandric, S, additional, Mehmedbegovic, Z, additional, Zivkovic, M, additional, Milasinovic, D, additional, Dedovic, V, additional, Tomasevic, M, additional, Orlic, D, additional, Vukcevic, V, additional, Beleslin, B, additional, Stankovic, G, additional, and Stojkovic, S, additional

Published
2018
Full Text
View/download PDF

15. P564Significance of heart rate recovery after exercise testing in patients with type 2 diabetes and silent myocardial ischemia

Author

Petrovic, M.T., primary, Boskovic, N., additional, Giga, V., additional, Rakocevic, I., additional, Trifunovic, D., additional, Dobric, M., additional, Tesic, M., additional, Aleksandric, S., additional, Orlic, D., additional, Nedeljkovic, I., additional, Saponjski, J., additional, Djordjevic-Dikic, A., additional, Beleslin, B., additional, Ostojic, M.C., additional, and Stepanovic, J., additional

Published
2017
Full Text
View/download PDF

16. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study

Author

Patti G, B?rczi G, Orlic D, Mangiacapra F, Colonna G, Pasceri V, Merkely B, Edes I, Ostojic M, Wijns W, Di Sciascio G., BARBATO, EMANUELE, Patti, G, B?rczi, G, Orlic, D, Mangiacapra, F, Colonna, G, Pasceri, V, Barbato, Emanuele, Merkely, B, Edes, I, Ostojic, M, Wijns, W, and Di Sciascio, G.

Published
2011

17. Rapid Fire Abstract session: multimodality imaging of ischaemic heart disease928Regional left ventricular longitudinal function and myocardial blood flow929The influence of plaque burden, morphology and inflammatory markers on coronary microvascular function in patients with chest pain and unobstructed coronary arteries930Predictors of coronary microcirculatory function after primary percutaneous coronary intervention in STEMI patients932Prediction of adverse events after ST segment-elevation myocardial infarction by imaging techniques933Echocardiography, contractile reserve and magnetic resonance to predict left ventricular remodelling934Relationship between the morphology of myocardial infarction scar border assessed by cardiac magnetic resonance and the inducibility of ventricular tachycardia935Comprehensive echocardiographic long-term risk stratification for the prediction of heart failure hospitalization and cardiovascular death following ST-segment elevation myocardial infarction

Author

Faber, L, primary, Nel, K T, primary, Trifunovic, D, primary, Rodero, S, primary, Hammache, N, primary, Olsen, F J, primary, Lindner, O, additional, Bogunovic, N, additional, Hering, D, additional, Burchert, W, additional, Horstkotte, D, additional, Senior, R, additional, Anstey, CM, additional, Begley, J, additional, Byrne, CD, additional, Kaski, J, additional, Bull, R, additional, Boos, CJ, additional, Greaves, K, additional, Stankovic, S, additional, Stepanovic, J, additional, Orlic, D, additional, Banovic, M, additional, Tesic, M, additional, Petrovic, O, additional, Petrovic, M, additional, Djordjevic-Dikic, A, additional, Vujisic-Tesic, B, additional, Mutuberria, M, additional, Rodriguez-Palomares, J, additional, Terricabras, M, additional, Gutierrez, L, additional, Teixido, G, additional, Galian, L, additional, Gonzalez-Alujas, T, additional, Evangelista, A, additional, Garcia-Dorado, D, additional, Voilliot, D, additional, Brembilla-Perrot, B, additional, Odille, F, additional, Felblinger, J, additional, Mandry, D, additional, Marie, PY, additional, Sadoul, N, additional, Huttin, O, additional, De Chillou, C, additional, Jensen, JS, additional, Pedersen, SH, additional, Nochioka, K, additional, and Biering-Sorensen, T, additional

Published
2015
Full Text
View/download PDF

22. Quantitative assessment of microcirculatory resistance in infarct-related and non-infarct-related coronary arteries in patients with ST-segment elevation myocardial infarction tretaed with primary PCI

Author

Orlic, D., primary, Ostojic, M., additional, Beleslin, B., additional, Tesic, M., additional, Sobic-Saranovic, D., additional, Stojkovic, S., additional, Vukcevic, V., additional, Stepanovic, J., additional, Nedeljkovic, M., additional, and Stankovic, G., additional

Published
2013
Full Text
View/download PDF

38. Transplantation of transduced nonhuman primate CD34+ cells using a gibbon ape leukemia virus vector: restricted expression of the gibbon ape leukemia virus receptor to a subset of CD34+ cells.

Author

Bunnell, B A, Kluge, K A, Lee-Lin, S-Q, Byrne, E R, Orlic, D, Metzger, M E, Agricola, B A, Wersto, R P, Bodine, D M, Morgan, R A, and Donahue, R E

Subjects
CELL transplantation, GENETIC transduction, GIBBONS, LEUKEMIA
Abstract

The transduction efficiencies of immunoselected rhesus macaque (Macaca mulatta) CD34+ cells and colony- forming progenitor cells based on polymerase chain reaction (PCR) analysis were comparable for an amphotropic Moloney murine leukemia virus (MLV) retroviral vector and a retroviral vector derived from the gibbon ape leukemia virus (GaLV) packaging cell line, PG13. On performing autologous transplantation studies using immunoselected CD34+ cells transduced with the GaLV envelope (env) retroviral vector, less than 1% of peripheral blood (PB) contained provirus. This was true whether bone marrow (BM) or cytokine-mobilized PB immunoselected CD34+ cells were reinfused. This level of marking was evident in two animals whose platelet counts never fell below 50000/μl and whose leukocyte counts had recovered by days 8 and 10 after having received 1.7 × 107 or greater of cytokine-mobilized CD34+ PB cells/kg. Reverse transcriptase(RT)-PCR analysis of CD34+ subsets for both the GaLV and amphotropic receptor were performed. The expression of the GaLV receptor was determined to be restricted to CD34+ Thy-1+ cells, and both CD34+ CD38+ and CD34+ CD38dim cells, while the amphotropic receptor was present on all CD34+ cell subsets examined. Our findings suggest that, in rhesus macaques, PG13-derived retroviral vectors may only be able to transduce a subset of CD34+ cells as only CD34+Thy-1+ cells express the GaLV receptor. [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

39. Outcome Comparison of 600- and 300-mg Loading Doses of Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Results From the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) Randomized Study

Author

Patti, G, Barczi, G, Orlic, D, Mangiacapra, F, Colonna, G, Pasceri, V, Barbato, E, Merkely, B, Edes, I, Ostojic, M, Wijns, W, and Di Sciascio, G

Subjects
clopidogrel, percutaneous coronary intervention, outcome, acute myocardial infarction, infarct size, cardiovascular diseases
Abstract

ObjectivesThe purpose of this study was to compare 600- and 300-mg clopidogrel loading doses in patients with ST-segment elevation myocardial infarction (STEMI).BackgroundGiven the high thrombotic risk of patients with STEMI, greater platelet inhibition may improve outcome in those patients receiving percutaneous coronary intervention (PCI). Although observational data suggest that pretreatment with a 600-mg clopidogrel loading dose may be more effective than the 300-mg regimen in primary PCI, this hypothesis has never been tested in a randomized study.MethodsA total of 201 patients undergoing primary PCI for STEMI randomly received a 600-mg (n = 103) or 300-mg (n = 98) clopidogrel loading dose before the procedure. The primary endpoint was the evaluation of the infarct size, defined as the area under the curve of cardiac markers.ResultsInfarct size was significantly lower in the high-dose regimen: median creatine kinase-myocardial band 2,070 ng/ml (interquartile range [IQR]: 815 to 2,847 ng/ml) versus 3,049 ng/ml (IQR: 1,050 to 7,031 ng/ml) in the 300-mg group, p = 0.0001; troponin-I 255 ng/ml (IQR: 130 to 461 ng/ml) versus 380 ng/ml (IQR: 134 to 1,406 ng/ml), p < 0.0001. In the 600-mg arm, Thrombolysis In Myocardial Infarction flow grade

Full Text
View/download PDF

41. Relations between biomechanical parameters and static power of arms in children with disturbed posture

Author

Andrasic, S., Milic, Z., Marko Cvetkovic, Ujsasi, D., and Orlic, D.

Subjects
lcsh:Sports, lcsh:GV557-1198.995, children, static power, biomechanical parameters, disturbed posture
Abstract

This study is aimed at determining the parameters and biomechanical analysis of their impact on the static arm strength in children with impaired posture as poor kyphotic posture, lordotic poor posture and children with flat feet. A transversal study included a sample of 67 children on the territory of the municipality of Subotica. The structure of the sample is as follows: 22 subjects with impaired kyphotic posture, 18 patients with impaired lordotic posture, and 27 subjects with flat feet. Measuring the level of static arm strength was done by the standardized "folding endurance" test. Observing the morphological development of children with kyphotic, lordotic poor posture and flat feet determined statistically significant differences in biomechanical variables.

42. P520 Percutaneous coronary intervention for chronic total occlusions of coronary arteries: procedural characteristics and long-term clinical outcomes.

Author

Jeremic, V, Stojkovic, S, Dobric, M, Vukcevic, V, Orlic, D, Cvorovic, I, and Vasiljevic-Pokrajcic, Z

Subjects
ANGIOPLASTY, ARTERIAL occlusions, ANGINA pectoris, CHEST pain, HEALTH outcome assessment, MEDICAL statistics
Abstract

Purpose: Despite the fact that techniques for recanalization of chronic total occlusions (CTO) are improved, the benefit of successful recanalization of the artery remains unclear. The aim of our study is to determine the success rate of percutaneous procedures and to evaluate the event free long-term survival in patients with CTO who underwent percutaneous coronary intervention (PCI).Methods: Our study included 283 consecutive patients with chronic total occlusions who underwent percutaneous coronary intervention on CTO at Clinic for Cardiology, between Jan 1st 2009 and Dec 31st 2010. Data were obtained retrospectively from Cath lab database at Clinic for Cardiology. Follow up data were obtained by direct phone contact.Results: Overall procedural success was achieved in 62.3% interventions. Independent predictors for procedural failure were presence of vessel tortuosity (P=0.007), vessel wall calcifications (P=0.000), blunt stump (P=0.000) and unstable angina pectoris as negative predictor (P=0.009). Overall MACE rates were similar in the procedural success and procedural failure groups (10% vs. 12.8%, p=0.455). There was no significant difference in the event free survival rate between success and failure group (89.8% vs. 87.2%, Log-Rank =0.468, p=0.494).Conclusions: Our study demonstrated that success rate of PCI in patients with CTO is acceptable and safe. Nevertheless, successful recanalization of CTO was not associated with an improved event free survival. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

43. Septic Sacroiliitis: An Analysis of 14 Patients

Author

Jajic, I., Furst, Z., Kralj, K., Ograjsek, A., Orlic, D., and Pecina, M.

Abstract

In most joints arthritis is easily diagnosed. This, however, is not the case with infectious sacroiliitis because of the inaccessibility of the sacroiliac joint, due to the anatomic and topographic relations.Fourteen patients with septic sacroiliitis in whom the diagnosis was established between 10 and 90 days after the onset of the disease are reported for a 5-year period. All patients had scintigraphic high uptake and three patients did not show any radiographic changes.

Published
1983
Full Text
View/download PDF

44. Unexpected Potential of Adult Stem Cells

Author

Yuehua Jiang, Robert E. Schwartz, Catherine M. Verfaillie, Morayma Reyes, Orlic, D, Brummendorf, TH, Fibbe, W, Sharkis, S, and Kanz, L

Subjects
Stem Cells, General Neuroscience, Cellular differentiation, Cell Differentiation, Amniotic stem cells, Biology, General Biochemistry, Genetics and Molecular Biology, Rats, Cell biology, Endothelial stem cell, Mice, History and Philosophy of Science, Organ Specificity, Animals, Humans, Cell Lineage, Progenitor cell, Stem cell, Cell potency, Stem Cell Transplantation, Adult stem cell, Stem cell transplantation for articular cartilage repair
Abstract

We have identified a population of primitive cells in normal human (h) as well as murine (m) and rat (r), postnatal bone marrow (BM) that have, at the single cell level, multipotent differentiation and extensive proliferation potential, which we named Multipotent Adult Progenitor Cell or MAPC. MAPC differentiate in vitro into most mesodermal cell types (cells with characteristics of osteoblasts, chondroblasts, fibroblasts, adipocytes, skeletal, smooth and cardiac myoblasts, endothelial cells), as well as cells with neuroectodermal and with endodermal features. Using retroviral marking we have shown that multi-lineage differentiation is derived from single MAPC. MAPC express active telomerase and can undergo 100+ cell doublings without telomere shortening, suggesting that they do not senesce. MAPC express oct-4 mRNA. MAPC engraft in vivo and persist for 6+ months, differentiate into hematopoietic and epithelial cells in response to local “cues”, and contribute to all somatic cell types when injected in the blastocyst. The finding that stem cells exist in post-natal tissues with previously unknown proliferation and differentiation potential opens up the possibility of using autologous stem cells to treat a host of degenerative, traumatic or congenital diseases.

Published
2003

45. Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) Study

Author

Emanuele Barbato, Fabio Mangiacapra, Dejan Orlic, Germano Di Sciascio, William Wijns, Miodrag Ostojic, Giuseppe Patti, Andrea D'Ambrosio, Aaron Peace, Mangiacapra, F, Patti, G, Barbato, Emanuele, Orlic, D, Peace, Aj, D'Ambrosio, A, Ostojic, M, Wijns, W, and Di Sciascio, G.

Subjects
medicine.medical_specialty, Internationality, Ticlopidine, medicine.medical_treatment, Myocardial Infarction, Infarction, Percutaneous Coronary Intervention, Postoperative Complications, Internal medicine, Angioplasty, medicine, Humans, ST segment, In patient, Prospective Studies, Myocardial infarction, Angioplasty, Balloon, Coronary, Dose-Response Relationship, Drug, business.industry, Medical school, Percutaneous coronary intervention, medicine.disease, Clopidogrel, humanities, Treatment Outcome, Cardiology, Cardiology and Cardiovascular Medicine, business, Platelet Aggregation Inhibitors, medicine.drug
Abstract

undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) Study Fabio Mangiacapra ⁎, Giuseppe Patti , Emanuele Barbato , Dejan Orlic , Aaron J. Peace , Andrea D'Ambrosio , Miodrag Ostojic , William Wijns , Germano Di Sciascio a,⁎,1 a Department of Cardiovascular Sciences, Campus Bio-Medico University, Rome, Italy b Cardiovascular Center Aalst, OLV Hospital, Aalst, Belgium c Department of Diagnostics and Catheterization Laboratories, Division of Cardiology, Clinical Center of Serbia, Medical School of Belgrade, Belgrade, Serbia

Published
2012

46. Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells

Author

Morayma Reyes, Catherine M. Verfaillie, Orlic, D, Brummendorf, TH, Sharkis, SJ, and Kanz, L

Subjects
Cellular differentiation, Becaplermin, Bone Marrow Cells, Cell Separation, Biology, General Biochemistry, Genetics and Molecular Biology, Mesoderm, Mice, History and Philosophy of Science, Animals, Humans, Cell Lineage, Progenitor cell, Cells, Cultured, Progenitor, Stem cell transplantation for articular cartilage repair, Bone Marrow Transplantation, Platelet-Derived Growth Factor, Epidermal Growth Factor, General Neuroscience, Stem Cells, Mesenchymal stem cell, Age Factors, Cell Differentiation, Proto-Oncogene Proteins c-sis, Telomere, Cell biology, Endothelial stem cell, Phenotype, Stem cell, Adult stem cell, Stem Cell Transplantation
Abstract

Mesenchymal stem cells were isolated and a subpopulation of cells--multipotent adult progenitor cells--were identified that have the potential for multilineage differentiation. Their ability to engraft and differentiate in vivo is under investigation. ispartof: pages:231-235 ispartof: Annals of the New York Academy of Sciences vol:938 pages:231-235 ispartof: 3rd International Conference on Hematopoietic Stem Cells: Genetics and Medicine location:GERMANY, TUBINGEN date:14 Sep - 16 Sep 2000 status: published

Published
2001

48. Successful Caesarean Section on Ticagrelor Treatment One Day after Primary Percutaneous Coronary Intervention.

Author

Antonijevic N, Mitrovic P, Gosnjic N, Orlic D, Kadija S, Ilic Mostic T, Savic N, Birovljev L, Lekovic Z, and Matic D

Abstract

Caesarean section is a challenging intervention in patients treated with dual antiplatelet therapy. We present a case of a 32-year-old pregnant woman experiencing large acute myocardial infarction (MI) of the anterolateral wall, complicated by cardiogenic shock in the 38th week of pregnancy, and treated with drug-eluting stent implantation and dual antiplatelet therapy (DAPT) consisting of aspirin and ticagrelor. Less than 24 h after the MI delivery started, an urgent Caesarean section was indicated. As multiplate aggregometry testing showed a relatively insufficient level of ticagrelor platelet inhibition and a moderate level of aspirin platelet inhibition, a Caesarean section was performed without discontinuation of ticagrelor, which was decided due to the need for emergency surgery. Local hemostatic measures including administration of tranexamic acid were applied. The patient did not experience excessive bleeding. A healthy male baby was born. To the best of our knowledge, this is the first reported case of surgery in pregnant women treated with DAPT without ticagrelor discontinuation.

Published
2023
Full Text
View/download PDF

49. Case report: Acute toxic myocardial damage caused by 5-fluorouracil-from enigma to success.

Author

Lasica R, Spasic J, Djukanovic L, Trifunovic-Zamaklar D, Orlic D, Nedeljkovic-Arsenovic O, and Asanin M

Abstract

Considering the pandemic of both cardiovascular diseases and oncological diseases, there is an increasing need for the use of chemotherapy, which through various pathophysiological mechanisms leads to damage to heart function. Cardio toxicity of chemotherapy drugs can manifest itself in a variety of clinical manifestations, which is why establishing a valid diagnosis is a real mystery for clinicians. Acute systolic heart failure (AHF) due to the use of 5-fluorouracil (5-FU) is a rare occurrence if it is not associated with myocardial infarction, myocarditis or Takotsubo cardiomyopathy. Therefore, we decided to present a case of an 52-year-old male who was diagnosed with stage IV RAS wild-type adenocarcinoma of the rectum and in whom the direct toxic effect 5-FU is the main reason for the appearance of toxic cardiomyopathy., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Lasica, Spasic, Djukanovic, Trifunovic-Zamaklar, Orlic, Nedeljkovic-Arsenovic and Asanin.)

Published
2022
Full Text
View/download PDF

50. Prognostic Value of Transthoracic Doppler Echocardiography Coronary Flow Velocity Reserve in Patients With Asymmetric Hypertrophic Cardiomyopathy.

Author

Tesic M, Beleslin B, Giga V, Jovanovic I, Marinkovic J, Trifunovic D, Petrovic O, Dobric M, Aleksandric S, Juricic S, Boskovic N, Tomasevic M, Ristic A, Orlic D, Stojkovic S, Vukcevic V, Stankovic G, Ostojic M, and Djordjevic Dikic A

Subjects
Adult, Blood Flow Velocity, Female, Humans, Male, Middle Aged, Prognosis, Cardiomyopathy, Hypertrophic diagnostic imaging, Cardiomyopathy, Hypertrophic physiopathology, Echocardiography, Doppler
Abstract

Background Microvascular dysfunction might be a major determinant of clinical deterioration and outcome in patients with hypertrophic cardiomyopathy (HCM). However, long-term prognostic value of transthoracic Doppler echocardiography (TDE) coronary flow velocity reserve (CFVR) on clinical outcome is uncertain in HCM patients. Therefore, the aim of our study was to assess long-term prognostic value of CFVR on clinical outcome in HCM population. Methods and Results We prospectively included 150 HCM patients (82 women; mean age 48±15 years). Patients' clinical characteristics, echocardiographic and CFVR findings (both for left anterior descending [LAD] and posterior descending artery [PD]), were assessed in all patients. The primary outcome was a composite of: HCM related death, heart failure requiring hospitalization, sustained ventricular tachycardia and ischemic stroke. Patients were stratified into 2 subgroups depending on CFVR LAD value: Group 1 (CFVR LAD>2, [n=87]) and Group 2 (CFVR LAD≤2, [n=63]). During a median follow-up of 88 months, 41/150 (27.3%) patients had adverse cardiac events. In Group 1, there were 8/87 (9.2%), whereas in Group 2 there were 33/63 (52.4%, P <0.001 vs. Group 1) adverse cardiac events. By Kaplan-Meier analysis, patients with preserved CFVR LAD had significantly higher cumulative event-free survival rate compared to patients with impaired CFVR LAD (96.4% and 90.9% versus 66.9% and 40.0%, at 5 and 8 years, respectively: log-rank 37.2, P <0.001). Multivariable analysis identified only CFVR LAD≤2 as an independent predictor for adverse cardiac outcome (HR 6.54; 95% CI 2.83-16.30, P <0.001), while CFVR PD was not significantly associated with outcome. Conclusions In patients with HCM, impaired CFVR LAD (≤2) is a strong, independent predictor of adverse cardiac outcome. When the aim of testing is HCM risk stratification and CFVR LAD data are available, the evaluation of CFVR PD is redundant.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results